LEAP-BIO

LEAP-BIO is a COSME project which aims to **develop IP licensing intermediary services** for early stage assets in **Pharma** and **BIOtech**.

This document was created to collect information about early-stage assets that match the in-licensing interests we collected from the big pharma and well-funded biotech companies. Please provide only non-confidential information. The matchmaking activities are human-curated, ensuring personalized and accurate matching of licensing interests with early-stage assets. In case there is an expression of interest from a company in your asset, you will be asked to provide us further information (a NDA may be set up at that time, if needed).

If you have any questions, please contact imm-techtransfer@medicina.ulisboa.pt

PARTNERSHIP:

Funded by the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily refl ect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.

Title:

ORGANIZATION:

RESEARCH TEAM:

Asset description:

Therapeutic area:

Please select the therapeutic area from the pdf 'Interests from big pharma & biotech'

Therapeutic sub-area:

If applicable, please select the therapeutic sub-area from the pdf 'Interests from big pharma & biotech'

Therapeutic indication:

Please select the therapeutic indication from the pdf 'Interests from big pharma & biotech'

Other :

If your therapeutic indication did not appeared in the previous list, please indicate it here

Category:

- ◯ Drug
- ◯ Target
- ◯ Enabling technology
- ◯ Other, please speficy:

If you selected 'Drug', please specify the therapeutic modality:

- ◯ Antibody
- ◯ Small molecule
- ◯ Gene therapy
- ◯ Cell therapy
- ◯ RNA-based therapy
- ◯ Peptide
- ◯ Protein
- ◯ Viral vectors
- ◯ DNA-repair inhibitors
- ◯ Vaccinology
- ◯ Biologics
- ◯ Advanced therapy
- ◯ Toxin
- ◯ Large mollecules
- ◯ Antibody-drug conjugates (ADC)
- ◯ Degraders (PROTACs, Molecular Glues)
- ◯ Milamolecules
- ◯ Other, please speficy:

If you selected 'Drug', please select the correct option :

- ◯ First-in-class
- ◯ Best-in-class

If you selected ‘Target’, please select the most suitable option :

If you selected ‘Enabling technology’, please select the category :

If you selected ‘Enabling technology’, please select most suitable option :

Target/mechanism of action :

Stage of development:

- ○ Target ID
- ○ Target validation
- ○ *in vitro* PoC
- ○ *in vivo* PoC
- ○ Hit ID
- ○ Hit to lead
- ○ Lead optimization
- ○ IND-enabling

Please provide an overview of the package of results you have:

IP protection status :

Track record :